Dr. Sergi Papiol

Since his early career steps as biology PhD student, Sergi Papiol (SP)’s research interests have focused on the genetic factors contributing to the complex phenotype of affective- and psychotic-spectrum disorders. Until 2022, he led the Genomics group at the Institute of Psychiatric Phenomics and Genomics (IPPG) at the Ludwig Maximilian University of Munich before moving to the Max-Planck Institute of Psychiatry in Munich. Importantly, he has been coordinating the second wave of training and data recruitment of the Consortium on Lithium Genetics (ConLiGen) since 2018. As a result of his involvement in ConLiGen, he has participated in several studies related to the genetic/polygenic bases of lithium response in bipolar disorder patients. A second relevant aspect of his work over the last years has been the analysis of a wide repertoire of biosamples (DNA, RNA, proteome, lipidome) with an untapped potential as biomarkers in psychiatry. SP is a member of the International Group for the Study of lithium-treated patients (IGSLi). SP is also part of the recently funded Psych-STRATA project (Horizon Europe program) on treatment stratification, in which he coordinates the biobanking of the samples derived from a large multi-centric study, and he also leads a work package dedicated to dissemination involving patients' organizations, professional societies, and scientific community.